Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?

Viking Therapeutics Inc. VKTX is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost 240% year-to-date, largely due to excitement surrounding its weight-loss drug candidate, VK2735.As a new contender in the burgeoning obesity drug market, Viking is not just riding the coattails of industry giants but actively challenging them.Weight-Loss Drug ShowdownViking's VK2735 mimics both GLP-1 and GIP hormones, ai ...